Learn to trade in these market conditions - Click here Just Released!
Paul Ruggieri's Medical Technology Insight
|
Paul Ruggieri M.D.
This week, the annual meeting of the American Diabetes
Association should focus the spotlight on many companies
developing new drug treatments for diabetes (see last week’s
biotech piece). Diabetes is a growing problem,
particularly in children, and costs this country’s healthcare
system billions of dollars. Despite being effective, today’s
treatment (more)
 Paul Ruggieri M.D.
The biotechs have experienced a nice run since March, a run fueled by anticipated positive news out of the recent ASCO meeting. Well, the meeting did not disappoint the medical profession (more)
Paul Ruggieri M.D.
Starting today, the 6th Annual Meeting of the American Society of Gene Therapy begins in Washington, DC, and with it begins more potential trading opportunities. This meeting, although not as popular as ASCO, is sexier than ASCO by way of its content. It brings together scientists and companies to discuss the latest cutting-edge research in gene therapy for a variety of diseases. The presentations at this meeting are pushing the envelope in applying gene therapy to the treatment of disease.
(more)
Paul Ruggieri M.D.
The American Society of Clinical Oncology’s annual meeting began this past weekend, and so far the early winner appears to be Genentech (DNA), on many fronts. (more)
Paul Ruggieri M.D.
Let the ASCO games begin. It looks like the ASCO floodgates have busted wide open, based on yesterday’s biotech’s wild ride. The momentum all started last week with Genentech’s (DNA) release of positive phase III data on its new anti-angiogenesis drug. The instigator yesterday was ImClone (IMCLE), with a news release before the opening bell. The company stated it would receive a $6 million milestone payment from its European partner Merck KGaA related to the upcoming release of phase III (more)
Paul Ruggieri, M.D.
It is only four days before the biggest meeting of
cancer specialists in the world…..and anything can
happen. Last Monday, Genentech (DNA) could not keep its
secret locked up any longer. On Monday morning, the
company fired the first preemptive shot by releasing positive
survival data on its new anti-angiogenesis drug Avastin for
the treatment (more)
Paul Ruggieri M.D.
Will yesterday’s wild ride for Genentech end? Yesterday, the company initiated a preemptive release of crucial phase III data on its developing anti-angiogenesis drug Avastin a week before the start of this year’s ASCO meeting. It was a thing of beauty and caught everyone off gu (more)
Paul Ruggieri M.D.
The 39th annual gathering of the American Society of Clinical Oncology (ASCO) is only eleven days away (May 31 to June 3) and already Wall Street speculation is brewing on which company will the toast of the meeting. The ASCO meeting is the largest of the year for cancer specialists to present (more)
Paul Ruggieri, M.D.
Conservative numbers show erectile dysfunction to
affect over 30 million men in this country and over 130
million worldwide. The current market for drugs to treat
ED is over $1.5 billion and expects to climb to $5 billion in
three years. Obviously, this target disease is a large
market with (more)
Paul Ruggieri M.D.
This week and next could prove to be very busy for stocks in
the biotech sector, for two reasons. As I mentioned in my
last article, on May 15 a FDA Advisory Panel will decide the
fate of the drug Xolair, a new approach to the treatment of
asthma in adolescents and adults. Three companies are
developing the drug: Tanox (TNOX), Genentech (DNA), and
Novartis (NVS). The Panel’s meeting on Thursday has all the
earmarking (more)
Paul Ruggieri, M.D.
This week’s initial biotech buzz will focus on the FDA’s
final approval of AstraZenca’s novel treatment for lung
cancer, an approval that should come today. The drug Iressa
is an entirely new approach to the treatment of cancer, an
approach that other companies are trying to mimic. Last
September (more)
Paul Ruggieri, MD
The annual meeting of the American Urological Association
(AUA) officially begins today in Chicago, highlighting new
advances in the treatment of a variety of urological
diseases. This is the major meeting for urologists all over
the world and a meeting that many on Wall Street keep an eye
on.
(more)
Paul Ruggieri, MD, FACS
On Sunday, March 30, the American College of Cardiology
holds its annual meeting in Chicago. The meeting is a
major forum for cardiologists from around the world to
present data on new drugs to treat all aspects of
cardiovascular (more)
Paul Ruggieri, MD
Over the next several weeks, two emerging biotechs will take
center stage when both release experimental drug data from
ongoing pivotal phase III clinical trials. The results
of these trials will have a lasting impact on each company’s
long-term financial health. For any biotech, the result of a
phase (more)
Paul Ruggieri, MD
We all know what March symbolizes for die-hard college hoop
fans, and I include myself in this fanatical group.
However, March is also the beginning of a hectic three-month
stretch that offers great opportunity for biotech
traders. For the next three months, many biotech
companies will experience sentinel events surrounding their
potential (more)
Paul Ruggieri, MD
VaxGen (VXGN) took investors for a wild ride yesterday after
the company released the United States clinical trial data of
its experimental AIDS vaccine -- and what a ride it
was. The much-anticipated results of this closely
watched (more)
Paul Ruggieri, MD
Well, the moment of truth has arrived for VaxGen’s vaccine
(AIDSVAX) designed to prevent HIV infection and I truly
admire (more)
Paul Ruggieri, MD, FACS
Since February has been designated “Heart Month,” I feel
obligated to shed some light on two biotechs with some very
exciting drugs in the developmental pipeline. There are
attractive qualities of these two companies that will garnish
a significant amount of investor attention as their drugs
approach (more)
Paul Ruggieri, M.D.
This has definitely not been a boring week for biotech. With acquisitions, a high-profile meeting on new drugs to treat HIV infection, quarterly earnings reports, and management changes the sector has experienced some excitement. The week started off with Johnson & Johnson’s [JNJ|JNJ] announcement (more)
Paul Ruggieri, MD
Today at noon Eastern Time, Feb. 11, VaxGen will hold a conference call discussing its earnings report for the quarter and year ended Dec, 31, 2002. The question on every trader’s mind is not whether the company made money last month or whether it will make money this year. The big question is w (more)
|
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
